HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

Mohamad A. Meybodi; Wenhao Cao; Leo Luznik; Asad Bashey; Xu Zhang; Rizwan Romee; Wael Saber; Mehdi Hamadani; Daniel J. Weisdorf; Haitao Chu; Armin Rashidi

Blood Advances (Sep 2019)

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

Mohamad A. Meybodi,
Wenhao Cao,
Leo Luznik,
Asad Bashey,
Xu Zhang,
Rizwan Romee,
Wael Saber,
Mehdi Hamadani,
Daniel J. Weisdorf,
Haitao Chu,
Armin Rashidi

Affiliations

Mohamad A. Meybodi: Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN
Wenhao Cao: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN
Leo Luznik: Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Asad Bashey: Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
Xu Zhang: Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX
Rizwan Romee: Division of Transplant and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Wael Saber: Blood and Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Mehdi Hamadani: Blood and Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Daniel J. Weisdorf: Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN
Haitao Chu: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN
Armin Rashidi: Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; Armin Rashidi, Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, 14-132 Phillips Wangensteen Building, 516 Delaware St SE, Minneapolis, MN 55455

Journal volume & issue: Vol. 3, no. 17
pp. 2581 – 2585

Abstract

Read online

Abstract: HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Published in Blood Advances

ISSN: 2473-9529 (Print); 2473-9537 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine
Website: https://ashpublications.org/bloodadvances

About the journal